These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18451013)

  • 1. NAMI perspective on CATIE: policy and research implications.
    Duckworth K; Fitzpatrick MJ
    Psychiatr Serv; 2008 May; 59(5):537-9. PubMed ID: 18451013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the CATIE findings on state mental health policy.
    Parks JJ; Radke AQ; Tandon R
    Psychiatr Serv; 2008 May; 59(5):534-6. PubMed ID: 18451012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
    Rosenheck RA; Lieberman JA
    J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of CATIE for mental health services researchers.
    Covell NH; Finnerty MT; Essock SM
    Psychiatr Serv; 2008 May; 59(5):526-9. PubMed ID: 18451010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006.
    Alessi-Severini S; Biscontri RG; Collins DM; Kozyrskyj A; Sareen J; Enns MW
    Psychiatr Serv; 2008 May; 59(5):547-53. PubMed ID: 18451015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.
    Law MR; Ross-Degnan D; Soumerai SB
    Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
    Rosenheck RA; Leslie DL; Doshi JA
    Psychiatr Serv; 2008 May; 59(5):515-20. PubMed ID: 18451007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Science to services: consumers need "real-world" science.
    Amador XF; Fitzpatrick M
    Schizophr Bull; 2003; 29(1):133-7. PubMed ID: 12908668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
    Berkowitz RL; Patel U; Ni Q; Parks JJ; Docherty JP
    J Clin Psychiatry; 2012 Apr; 73(4):498-503. PubMed ID: 22226332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
    Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
    Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What CATIE did: some thoughts on implications deep and wide.
    Owens DC
    Psychiatr Serv; 2008 May; 59(5):530-3. PubMed ID: 18451011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.